Gilead Reaffirms Outlook As Q3 Earnings Miss The Mark

Share This Article
November 1, 2016 4:26pm NASDAQ:GILD

gilead-logoBiotech giant Gilead Sciences, Inc. (NASDAQ:GILD) late today posted disappointing third quarter earnings results, but stood by its full-year forecast despite lagging sales in all geographical regions.


The Foster City, CA-based company reported Q3 EPS of $2.75, missing Wall Street’s $2.84 estimate by nine centers. Revenue fell to $7.4 billion from $8.2 billion last year, in-line with analysts’ view.

Gilead said that sales for the third quarter in the United States were $5.1 billion, with $1.4 billion in Europe, $452 million in Japan, and $479 million in all other locations. Sales in each of those geographic regions fell from last year’s totals.

Antiviral product sales, which mostly include HIV and liver disease treatments, were $6.8 billion in Q3 2016, versus $7.7 billion in the year-ago period. for the same period in 2015. Other product sales $564 million in the latest quarter.

Looking ahead, GILD reiterated its previously-announced full-year 2016 revenue outlook of $29.5 to 30.5 billion, which could miss Wall Street’s $30.38 billion estimate.

The company commented via press release:

As of September 30, 2016, Gilead had $31.6 billion of cash, cash equivalents and marketable securities compared to $24.6 billion as of June 30, 2016. This increase was primarily due to the issuance of $5.0 billion aggregate principal amount of senior unsecured notes in September 2016. Cash flow from operating activities was $4.3 billion for the quarter. During the third quarter and the first nine months of 2016, Gilead utilized $1.0 billion and $10.0 billion on stock repurchases, respectively.

GILD also announced its fourth quarter dividend of $0.47 per share, which is payable on December 29, 2016, to stockholders of record as of December 15, 2016.

Gilead shares rose $0.53 (+0.72%) to $74.60 in after-hours trading. Prior to today’s report, GILD had fallen 26.8%.

GILD-2016-11-01


9 "Must Own" Growth Stocks For 2019

Read Next



Get Free Updates

Join over 50,000 investors who get the latest news from ETFDailyNews.com!

Most Popular



Explore More from ETFDailyNews.com

Free Daily Newsletter

Get daily ETF insights from our market experts. Never miss another important market development again!

ETFDailyNews.com respects your privacy.

Best ETFs

We've rated and ranked nearly 2,000 ETFs and ETNs using our proprietary SMART Grade system.

View Top Rated ETFs

Best Categories

We've ranked dozens of ETF categories based on relative performance.

Best ETF Categories